Status:
COMPLETED
Ziprasidone in the Treatment of Borderline Personality Disorder
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Collaborating Sponsors:
Ministry of Health, Spain
REM-TAP Network
Conditions:
Borderline Personality Disorder
Eligibility:
All Genders
18-45 years
Phase:
PHASE2
Brief Summary
Objective: The aim of this double-blind, placebo-controlled study was to evaluate the efficacy and tolerability of ziprasidone in the treatment of adult patients with Borderline Personality Disorder (...
Detailed Description
The American Psychiatric Association (APA) Guidelines for the Treatment of Borderline personality disorder recommend that pharmacological treatment for BPD has an important adjunctive role, especially...
Eligibility Criteria
Inclusion
- DSM-IV diagnosis of Borderline Personality Disorder
- Age between 18 and 45 years
- Clinical Global Impression of Severity (CGI-S)scores \>4
Exclusion
- No comorbidity with schizophrenia, drug-induced psychosis, organic brain syndrome, alcohol or other substance dependence, bipolar disorder, mental retardation, or major depressive episode in course
- current use of medically accepted contraception in the case of female patients.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00635921
Start Date
March 1 2004
End Date
April 1 2006
Last Update
March 14 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry, Sta. Creu and St. Pau Hospital
Barcelona, Spain, 08025